【摘要】 异基因外周血造血干细胞移植是目前能够治愈急性白血病的最佳方法,随着国内独生子女家庭的日益增多,同胞供体减少,从中华骨髓库中检索配型全相合造血干细胞供者概率较低,耗时长,而单倍体造血干细胞移植如能成功开展将是解决供者来源困难的主要手段,但其面临植入困难和移植物抗宿主病发生率高且重这两大风险。通过改良预处理方案及在经典的环孢素A+短程甲氨蝶呤的基础上,加用霉酚酸脂、白细胞介素11、抗人淋巴细胞免疫球蛋白及经重组人粒细胞集落刺激因子动员后的供体造血干细胞输注给受体联合预防移植物抗宿主病,成功的进行了2例单倍体外周血造血干细胞移植,2例患者均顺利植入,且无严重的移植物抗宿主病。更多还原

【Abstract】 Allotransplantation of peripheral blood-derived hemopoietic stem cells is the best therapy for acute leukemia. With increases of only-child families, sibling donors are decreasing. Moreover, the probability is low and time consuming is long to search a matched hemopoietic stem cell donor from the Chinese Marrow Donor Program. Haploidentical stem cell transplantation would bring a hope for donor resource. However, difficult transplantation and high incidence of graft versus host disease are two risks. Based on modified regimen and cyclosporine A+short-term amethopterin, mycophenolic acid, interleukin-11, anti-lymphocyte immunoglobulin and hemopoietic stem cells mobilized by recombinant human granulocyte colony-stimulating factor can prevent graft versus host disease. This therapy succeeded in two cases with no severe graft versus host disease.更多还原